UNITED STATES NEWS

US adds Merck pill as 2nd easy-to-use drug against COVID-19

Dec 23, 2021, 8:03 AM | Updated: Dec 24, 2021, 10:59 pm

WASHINGTON (AP) — U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.

The Food and Drug Administration announcement on Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer.

Pfizer’s pill, Paxlovid, is likely to become the first-choice treatment against the virus, because of its superior benefits and milder side effects.

As a result, Merck’s pill is expected to have a lesser role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.

Both treatments will be free to patients in the U.S. after being purchased by the federal government.

The FDA authorized Merck’s drug for adults with a positive COVID-19 test, early symptoms and who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease.

The agency said molnupiravir should be considered for patients “for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.” It did not include that restriction for Paxlovid, which was authorized for patients 12 and older.

Molnupiravir, made by Merck and Ridgeback Biotherapeutics, also will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said. The federal agency also said molnupiravir should not be used in patients under age 18 because it may affect bone growth.

Dr. Nick Kartsonis, Merck’s senior vice president of clinical research, said company scientists are still studying the drug and they hope to eventually get it approved for use in children.

The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.

Kartsonis said Merck researchers are “very comfortable” with their drug’s safety profile.

He also noted that molnupiravir has been studied in more than a thousand people, and researches saw side effects like diarrhea and nausea in only a small percentage of patients.

“The drug has actually looked very well tolerated,” he said.

Pfizer’s Paxlovid also comes with limitations. Regulators say doctors have to consider how it will interact with other medicines a patient may be taking, and they’ve noted it shouldn’t be prescribed to patients with severe liver or kidney problems.

Both treatments also should be started within five days of the beginning of symptoms, a deadline that puts pressure on patients to get tested and diagnosed quickly.

The two pills work differently and Pfizer’s doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.

Some experts question whether there will be much of a role for the Merck drug in the U.S.

“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”

For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant.

The seven-day rolling average for U.S. COVID-19 cases climbed past 160,000 Wednesday, according to data collected by Johns Hopkins University. That’s more than double the average in late November.

Antiviral pills like Merck’s and Pfizer’s are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.

Researchers have warned that older COVID-19 treatments that are administered by IV are unlikely to work against the new strain.

The FDA based its Merck decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.

Merck says several hundred thousand treatment courses will be available in the U.S. in the next several days and a million will be available over the next few weeks. The supply of Pfizer’s drug is more limited before ramping up in 2022.

The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.

Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.

___

AP Health Writer Tom Murphy contributed to this report.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

United States News

Republican presidential candidate former President Donald Trump speaking during the Republican Nati...

Associated Press

FACT FOCUS: A look at claims made at the Republican National Convention as Trump accepts nomination

As former President Donald Trump accepted the Republican presidential nomination on Thursday he laid out his vision for running the country. He painted a dire picture of the state of the U.S. and outlined a range of actions he planned to take. But his comments were marked with a myriad of false and misleading information […]

3 hours ago

Dr. Max Rogers, the obstetrician-gynecologist at Grove Hill Memorial Hospital, poses for a photo Mo...

Associated Press

Alabama birthing units are closing to save money and get funding. Some say babies are at risk

GROVE HILL, Ala. (AP) — One of the last remaining birthing units in southern Alabama will close next month to qualify for federal funding that will save the hospital’s emergency services, but doctors warn the move may cost newborns and pregnant women essential access to obstetric care. Nestled in rural Clarke County, the small, nonprofit […]

4 hours ago

Jim, left, and Tamara Hamilton watch former President Donald Trump speak on television on Thursday,...

Associated Press

Some GOP voters welcome Trump’s somewhat softened tone at Republican National Convention

For those conservative voters long turned off by former President Donald Trump’s rhetoric, his somewhat softened tone in accepting the Republican nomination Thursday night was a welcome relief. “He’s much improved,” Dave Struthers, a 57-year-old farmer from Collins, Iowa, said as he watched Trump’s speech in the basement of his farmhouse. “The thing I’ve had […]

4 hours ago

FILE - Former President Barack Obama speaks in Athens, Greece, June 21, 2023. Democrats at the high...

Associated Press

Obama’s dilemma: Balancing Democrats’ worry about Biden and maintaining influence with president

WASHINGTON (AP) — Former President Barack Obama has a delicate balance to strike: how to weigh the mounting opposition to President Joe Biden continuing his campaign with his loyalty to his former running mate. In recent days, Obama has taken calls from congressional leaders, Democratic governors and key donors in which he has shared their […]

4 hours ago

Vice President Kamala Harris arrives for an Asian and Pacific Islander American Vote Town Hall, Sat...

Associated Press

Majority of Democrats think Kamala Harris would make a good president, AP-NORC poll shows

WASHINGTON (AP) — As President Joe Biden faces a growing drumbeat of pressure to drop his reelection bid, a majority of Democrats think his vice president would make a good president herself. A new poll from the AP-NORC Center for Public Affairs Research found that about 6 in 10 Democrats believe Kamala Harris would do […]

4 hours ago

Associated Press

How bootcamps are helping to address the historic gap in internet access on US tribal lands

There’s a home movie theater with orange walls and plush recliners at the top of a steep hill on Matthew Rantanen’s ranch in Southern California. But on a recent afternoon, people weren’t flocking to the room to watch a movie or to escape the scorching heat, they were shining a beam of light through more […]

5 hours ago

Sponsored Articles

...

Midwestern University

Midwestern University Clinic visits boost student training & community health

Going to a Midwestern University Clinic can help make you feel good in more ways than one.

...

COLLINS COMFORT MASTERS

Here are 5 things Arizona residents need to know about their HVAC system

It's warming back up in the Valley, which means it's time to think about your air conditioning system's preparedness for summer.

...

Midwestern University

Midwestern University Clinics: transforming health care in the valley

Midwestern University, long a fixture of comprehensive health care education in the West Valley, is also a recognized leader in community health care.

US adds Merck pill as 2nd easy-to-use drug against COVID-19